Related Experiment Video

Updated: Feb 28, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization

Geon Yoo1, Tackhoon Kim2, Chaeuk Chung3

  • 1School of Biological Sciences, Seoul National University, Seoul 151-742, South Korea.

Biochemical and Biophysical Research Communications
|June 22, 2017
PubMed

Insights

Serum/glucocorticoid regulated kinase 1 (SGK1) acts as a positive feedback regulator for Yes-associated protein (YAP) and transcription activator with PDZ binding motif (TAZ). SGK1 stabilizes YAP/TAZ, enhancing their oncogenic activity.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Signal Transduction

Background:

  • Yes-associated protein (YAP) and transcription activator with PDZ binding motif (TAZ) are key regulators in tissue regeneration and cancer.
  • Serum/glucocorticoid regulated kinase 1 (SGK1) is implicated in various oncogenic pathways.
  • The interplay between SGK1 and the Hippo-YAP/TAZ signaling pathway is not well understood.

Purpose of the Study:

  • To investigate the regulatory relationship between SGK1 and YAP/TAZ signaling.
  • To elucidate the role of SGK1 in YAP/TAZ-mediated oncogenicity.

Main Methods:

  • Analysis of SGK1 transcription activation by TEAD-YAP/TAZ complex.
  • Assessment of SGK1's effect on YAP/TAZ protein stability.
  • Investigation of SGK1's impact on YAP/TAZ target gene expression.
  • Exploration of SGK1's mechanism in regulating TAZ degradation via GSK3β inhibition.

Main Results:

  • The TEAD-YAP/TAZ complex directly upregulates SGK1 transcription.
  • SGK1 enhances the stability of YAP and TAZ proteins.
  • SGK1 positively regulates the expression of YAP/TAZ target genes.
  • SGK1 inhibits the degradation of TAZ by suppressing GSK3β activity.

Conclusions:

  • SGK1 acts as a positive feedback regulator of YAP/TAZ signaling.
  • This interaction expands the understanding of YAP/TAZ regulation, identifying SGK1 as a novel downstream target.
  • The findings highlight SGK1 as a potential therapeutic target in cancers driven by YAP/TAZ hyperactivity.
Keywords:
Hippo pathwaySGK1TAZYAP

More Related Videos

De Novo Generation of Somatic Stem Cells by YAP/TAZ13:05

De Novo Generation of Somatic Stem Cells by YAP/TAZ

Published on: May 7, 2018

9.7K
Culturing and Manipulation of O9-1 Neural Crest Cells08:32

Culturing and Manipulation of O9-1 Neural Crest Cells

Published on: October 9, 2018

11.2K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53